10-Q quarterly report · filed Nov 6, 2026

TREACE MEDICAL CONCEPTS, INC. (TMCI) Q3 2026 10-Q Quarterly Report

Short answer

TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $48M (down 3.9% year over year) with net income of −$13M.

Q3 2026 key financials · XBRL

Revenue
$48M
−3.9% YoY · +6.3% QoQ
Net income
−$13M
+22.9% YoY · +20.8% QoQ
Operating margin
-23.9%
Gross margin
79.5%
EPS (diluted)
−$0.19
+26.9% YoY · +20.8% QoQ

Source: XBRL data from the TREACE MEDICAL CONCEPTS, INC. (TMCI) Q3 2026 10-Q on SEC EDGAR. USD.

TREACE MEDICAL CONCEPTS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $48.3M, down 3.9% YoY from $50.2M
  • Gross margin 79.5% vs 79.1% YoY, supported by $0.7M IEEPA tariff refunds
  • Worst performer: stocking distributor sales, down $5.1M YoY
  • Operating cash flow use $0.7M, versus $7.9M in prior-year period
  • Outlook: macroeconomic pressures, competition, pricing concessions, and lower-priced products remain headwinds

Risk Factors

  • No material changes from 2025 Form 10-K risk factors
  • Significant carried-forward risks remain unchanged, including regulatory compliance exposure
  • Operating risks remain unchanged, including competition and procedure adoption
  • Financial risks remain unchanged, including liquidity and capital requirements

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other TREACE MEDICAL CONCEPTS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.